1Hojs R, Bevc S, Ekart, et al. Serum cystatin C-based e- quation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney diseas[J].Clin Nophrol, 2008,70 ( 1 ) : 10- 17.
2[Galina KS, Wang B, Libby P,et al. Cystatin c deficiency increase elastic lamina degradation and aortic dilatation in apoliprotei E-nullmice[J]. Circ Res, 2005, 96 (3): 368- 375.
3Per E, Hiroyuki D, Ann S,et al. Human evidence that the cystatin c is implicated in focal progression of coronary artery disease[J].Arteriosclerosis, Thrombosis, and vas- cular Biology, 2004,24 (3) : 551-557.
4Kestenbaum B,Rudser KD,de Boer IH,et al. Differences in kidney function and incident hypertension: the multi- ethnic study of atherosclerosis[J]. Ann intern Med,2008, 148(7) :501-508.
5Donahue RP,Stranges S,Rejman K,et al. Elevated cysta- tin C concentration and progression to pre-diabetes The Western New York Study[J]. Diabetes Care; 2007, 30 (7) : 1724-1729.
7Cepeda J, Tranche-Iparraguirre S, Marin-Iranzo R, et al. Cystatin C and cardiovascular risk in the general popula- tion[J].Rev Esp Cardiol, 2010,63 (4) : 415-422.
10Kiyosue A, Hirata Y, Ando J, et al. Plasma cystatin C concentration relects the severity of coronary artery dis- ease in patients without chronic kidney disease[J]. Cite J ,2010,74(11) : 2441-2447.
7Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low- density lipoprotein biomarkers in cardiovascular disease [ J ]. Curt Opin Lipidol, 2006,17 (5) :502 - 509.
8Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a) : short - term and long - term immunologic responses to oxidized low- density lipoprotein[ J]. Circulation,2004,109(25 ) : 3164 - 3170.
9Bokenkamp A, Herget - Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease [J]. Pediatr Nephrol,2006,21 (9) : 1223 -1230.
10Lay IS, Hsieh CC, Chiu JH, et al. Salvianolic acid B enhances in vitro angiogenesis and improves skin flap survival in Sprague - Dawley rats [ J ]. J Surg Res, 2003,115 (2) : 279 - 285.
2Erkinjantti T.Diagnosis and management of vascular cognitive impairment and dementia[J].J Neural Transm Suppl,2002(63):91-l09.
3Liu P, Ma F, Lou H, et al. Relationship between cystatin C and met- abolic syndrome among Chinese premenopausal and postmenopausal women without recognized chronic kidney disease [ J ]. Menopause, 2015,22(2) :217 -223.
4Patel D,Ahmad S,Silverman A,et al. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postm- enopausal women with angiographically decompensated coronary ar- tery disease (from the Womertg Angiographic Vitamin and Estrogen [WAVE] study)[J]. Am J Cardiol,2013,111 (12):1681 -1687.
5Yunke Z, Guoping L,Zhenyue C. Triglyceride - to - HDL cholesterol ratio. Predictive value for CHD severity and new - onset heart fail- ure[J]. Herz,2014,39( 1 ) :105 - 110.
6Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C : an e- merging biomarker in cardiovascular disease [J]. Curr Top Med Chem,2013,13(2) :164 - 179.
7Doganer YC, Aydogan U ,Aparei M, et al. Comparison of cystatin - C and pentraxin -3 in coronary atherosclerosis [ J ]. Coron Artery Dis, 2014,25(7) :589 -594.
8Shi GP,Sukhova GK,Grubb A,et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms [ J ]. J Clin Invest, 1999,104 (9) :1191 - 1197.
9Xie L, Terrand J,Xu B, et al. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation [ J ]. Cardiovasc Res,2010,87(4) :628 -635.
